About this episode
In this episode of Talking HealthTech, Peter Birch speaks with Associate Professor Colman Taylor and Alasdair Godfrey from HTANALYSTS about the evolving landscape of health technology assessment in Australia.The conversation explores how regulatory change, patient engagement and real-world evidence are reshaping the way new technologies are assessed, funded and adopted.It also examines the challenges health tech companies face when bringing innovation to market in Australia and across international settings.They share practical insights into what these changes mean for innovators, clinicians and policy-makers navigating an increasingly complex system.This episode looks at how value is defined beyond the limits of clinical trials. It also highlights why patient experience and practical implementation are becoming increasingly important in decisions about health technology.Together, these insights offer a grounded and timely perspective on the forces shaping the future of Australian health technology.Key Takeaways? The "valley of death" is a significant hurdle for Australian health tech innovators, where promising technologies struggle to secure funding and market access.? Health Technology Assessment (HTA) frameworks are adapting to consider new dimensions such as equity, patient-centred outcomes, and system impact, beyond traditional cost and clinical effectiveness.? Patient engagement is increasingly recognised as critical, with patients now actively involved in advisory boards and decision-making processes, offering perspectives beyond those of clinicians.? Real-world evidence is helping to fill gaps left by clinical trials, providing insight into system readiness, implementation feasibility, and outcomes for diverse populations.? International policy changes, particularly from the US and UK, are influencing Australia’s HTA processes and impacting access to innovative therapies for patients.Timestamps00:00:00 – Introduction00:02:05 – Overview of HTANALYSTS and their purpose00:03:26 – The “valley of death”00:05:56 – Explaining Health Technology Assessment00:07:09 – Traditional metrics vs. evolving HTA frameworks00:08:33 – Government reviews in HTA00:10:46 – The role of patient engagement and inclusion in HTA00:12:29 – Application of patient engagement00:14:10 – Real-world evidence: its role and impact00:16:27 – Faster access, data barriers, and implementation challenges00:18:21 – Agility in assessment processes00:20:09 – Examples of flexibility in healthcare guidelines00:22:26 – What innovators can do now00:23:47 – MFN policy changes in the US00:26:07 – HTANALYSTS’ role as middlemen bridging stakeholders00:27:15 – Lessons about collaboration, evidence, and early alignment00:29:06 – Importance of implementation
